title: A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma.
authors.forename: J C
authors.initials: JC
authors.lastname: Morris
authors.forename: W J
authors.initials: WJ
authors.lastname: Ramsey
authors.forename: O
authors.initials: O
authors.lastname: Wildner
authors.forename: H A
authors.initials: HA
authors.lastname: Muslow
authors.forename: E
authors.initials: E
authors.lastname: Aguilar-Cordova
authors.forename: R M
authors.initials: RM
authors.lastname: Blaese
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics*
chemical_list: D000998:Antiviral Agents; D013937:Thymidine Kinase; D015774:Ganciclovir